.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
QuintilesIMS
Fuji
Accenture
US Army
Farmers Insurance
Novartis
Mallinckrodt
Express Scripts
Johnson and Johnson

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,101,629

« Back to Dashboard

Which drugs does patent 8,101,629 protect, and when does it expire?


Patent 8,101,629 protects COMPLERA, EDURANT, and ODEFSEY, and is included in three NDAs. There has been one Paragraph IV challenge on Complera.

This patent has one hundred and seventy patent family members in thirty-eight countries.

Summary for Patent: 8,101,629

Title:Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl- ]amino]benzonitrile
Abstract: The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino- ]benzonitrile and to processes for their preparation.
Inventor(s): Guillemont; Jerome Emile Georges (Ande, FR), Stevens; Paul Theodoor Agnes (Turnhout, BE), Copmans; Alex Herman (Lille, BE), Peeters; Jozef (Beerse, BE), Stappers; Alfred Elisabeth (Oud-Turnhout, BE), Vandecruys; Roger Petrus Gerebern (Westerlo, BE), Stoffels; Paul (Hoogstraten, BE)
Assignee: Janssen Pharmaceutica N.V. (Beerse, BE)
Application Number:12/845,463
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead Sciences IncCOMPLERAemtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarateTABLET;ORAL202123-001Aug 10, 2011RXYesYes► Subscribe► SubscribeY► Subscribe
Janssen ProdsEDURANTrilpivirine hydrochlorideTABLET;ORAL202022-001May 20, 2011RXYesYes► Subscribe► SubscribeY► Subscribe
Gilead Sciences IncODEFSEYemtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarateTABLET;ORAL208351-001Mar 1, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,101,629

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
EP01203090Aug 13, 2001
EP02077748Jun 10, 2002
MalaysiaPI20043578Sep 02, 2004
PCT/EP2004/052028Sep 03, 2004
05101467Feb 25, 2005

Non-Orange Book Patents for Patent: 8,101,629

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,841,310Combinations of a pyrimidine containing NNRTI with RT inhibitors► Subscribe
7,125,879HIV inhibiting pyrimidines derivatives► Subscribe
9,580,392HIV replication inhibiting pyrimidines► Subscribe
8,080,551HIV inhibiting pyrimidines derivatives► Subscribe
7,956,063Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl- ]amino]benzonitrile► Subscribe
7,638,522Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl- ]amino] benzonitrile► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,101,629

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2537095► Subscribe
Canada2577273► Subscribe
Canada2577288► Subscribe
China1541215► Subscribe
China100509801► Subscribe
China101056673► Subscribe
China101060844► Subscribe
China101068597► Subscribe
China101816658► Subscribe
China102319433► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Teva
Cipla
US Department of Justice
Boehringer Ingelheim
Chubb
Novartis
Medtronic
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot